A case control study of CSF copper, iron and manganese in Parkinson disease.
To elicit possible variations in the CSF concentrations of copper, iron and manganese due to Parkinson disease (PD) or to the stage reached, we tested 11 patients with idiopathic PD, 6 untreated and 5 on long term L-dopa, versus 22 age and sex matched patients with other neurological disorders (control group-CG). The CSF levels of the three metals, measured by electrothermal atomization, did not differ significantly between the PD group and CG or between either of the PD subgroups and CG. Our findings therefore do not support the hypothesis that CSF Cu is a marker of PD.
Gazzaniga
G C
GC
Divisione di Neurologia 2a, Ospedali Riuniti, Bergamo.
Ferraro
B
B
Camerlingo
M
M
Casto
L
L
Viscardi
M
M
Mamoli
A
A
D000368:Aged; D016022:Case-Control Studies; D003300:Copper / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D007501:Iron / Q000134:cerebrospinal fluid*; D008297:Male; D008345:Manganese / Q000134:cerebrospinal fluid*; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid*
D008345:Manganese; D003300:Copper; D007501:Iron